← All drugs
Drug · FAERS side-effect profile with label screen

Hydrocodone Bitartrate and Acetaminophen side effects: what 56,016 FDA adverse event reports show

Hydrocodone Bitartrate And Acetaminophen · 1,160 reaction terms · 210,231 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Label matched

Hydrocodone Bitartrate (Hydrocodone Bitartrate)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

56,016 reports · 86% serious · 8,227 with death outcome · 49% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Hydrocodone bitartrate extended-release tablets are indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limita.

FDA label, Indications and Usage

What it is

Hydrocodone bitartrate extended-release tablets are supplied in 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg and 120 mg film-coated tablets for oral administration. The tablet strengths describe the amount of hydrocodone per tablet as the bitartrate salt. Hydrocodone bitartrate is an opioid agonist.

FDA label, Description section

Boxed warning

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate extended-release tablets exposes patients and othe.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 3Labeled (related wording) 5Reporting / coding artifact 6Lab value / disease marker 1Not in label — unassessed 25
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,120 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Vision abnormal neonatal228442.0
364.7–535.8ROR 443.8 · calibrated p 3e-13 ✓
198.1 EB05 177.5 · IC025 +6.9
3/3 methods agree
Not in label — unassessedserious n=228 · 100% consumerno trial arm names this drug
Neonatal hypoacusis109326.4
252.3–422.4ROR 327.1 · calibrated p 9e-12 ✓
168.5 EB05 143.5 · IC025 +6.3
3/3 methods agree
Not in label — unassessedserious n=109 · 100% consumerno trial arm names this drug
Learning disability2,407303.9
288.1–320.5ROR 317.5 · calibrated p 6e-12 ✓
166.7 EB05 161.2 · IC025 +7.3
3/3 methods agree
Not in label — unassessedserious n=2,403 · 99% consumerno trial arm names this drug
Developmental delay2,240122.4
116.8–128.3ROR 127.5 · calibrated p 2e-8 ✓
92.1 EB05 88.9 · IC025 +6.4
3/3 methods agree
Not in label — unassessedserious PRR 62.2 · 99% consumerno trial arm names this drug
Drug dependence33,29596.4
95.6–97.2ROR 236.1 · calibrated p 9e-11 ✓
76.6 EB05 75.9 · IC025 +6.2
3/3 methods agree
Reporting / coding artifactserious PRR 52.1 · 98% consumerno trial arm names this drug
Imprisonment20748.8
42.2–56.4ROR 49.0 · calibrated p 2e-5 ✓
43.1 EB05 38.4 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=207 · ♀ 28% (drug 49%) · 97% consumerno trial arm names this drug
Disability1,76736.7
34.9–38.5ROR 37.8 · calibrated p 7e-5 ✓
33.4 EB05 32.1 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious PRR 23.0 · 95% consumerno trial arm names this drug
Emotional distress10,84236.6
36.0–37.3ROR 45.2 · calibrated p 3e-5 ✓
33.4 EB05 32.9 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious PRR 23.6 · 94% consumerno trial arm names this drug
Alcoholic1632.4
19.4–54.0ROR 32.4 · calibrated p 4e-4 ✓
28.9 EB05 18.9 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=16no trial arm names this drug
Spina bifida16331.4
26.7–36.8ROR 31.5 · calibrated p 2e-4 ✓
28.9 EB05 25.4 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=163 · 100% consumerno trial arm names this drug
Post-traumatic stress disorder51731.2
28.5–34.1ROR 31.4 · calibrated p 2e-4 ✓
28.8 EB05 26.8 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=513 · 96% consumerno trial arm names this drug
Overdose14,51126.8
26.4–27.2ROR 35.9 · calibrated p 1e-4 ✓
25.1 EB05 24.7 · IC025 +4.6
3/3 methods agree
Reporting / coding artifactserious PRR 21.1 · 97% consumerno trial arm names this drug
Drug withdrawal syndrome5,34524.0
23.3–24.6ROR 26.4 · calibrated p 5e-4 ✓
22.6 EB05 22.0 · IC025 +4.4
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 18.8 · 95% consumerno trial arm names this drug
Detoxification2123.9
15.4–37.2ROR 24.0 · calibrated p 0.001 ✓
22.1 EB05 15.2 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=21no trial arm names this drug
Mental disability3322.6
15.9–32.1ROR 22.6 · calibrated p 0.002 ✓
21.1 EB05 15.7 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=33 · 100% consumerno trial arm names this drug
Judgement impaired7419.9
15.7–25.1ROR 19.9 · calibrated p 0.002 ✓
18.8 EB05 15.5 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=74 · 100% consumerno trial arm names this drug
Exposure via father5014.7
11.1–19.5ROR 14.7 · calibrated p 0.009 ✓
14.0 EB05 10.9 · IC025 +3.2
3/3 methods agree
Reporting / coding artifactserious n=48 · 100% consumerno trial arm names this drug
General physical condition abnormal24113.7
12.1–15.6ROR 13.8 · calibrated p 0.010 ✓
13.2 EB05 11.9 · IC025 +3.5
3/3 methods agree
Lab value / disease markerserious n=240 · 100% consumerno trial arm names this drug
Substance use disorder10713.5
11.1–16.3ROR 13.5 · calibrated p 0.011 ✓
12.9 EB05 11.0 · IC025 +3.3
3/3 methods agree
Labeled adverse reaction
exact term
serious n=106 · 100% consumerno trial arm names this drug
Mental disorder1,49613.3
12.6–14.0ROR 13.6 · calibrated p 0.010 ✓
12.8 EB05 12.3 · IC025 +3.6
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 10.1 · 95% consumerno trial arm names this drug
Tobacco abuse1812.9
8.0–20.6ROR 12.9 · calibrated p 0.018 ✓
11.5 EB05 7.2 · IC025 +2.5
3/3 methods agree
Reporting / coding artifactserious n=18no trial arm names this drug
Theft2212.7
8.3–19.4ROR 12.7 · calibrated p 0.018 ✓
11.6 EB05 7.6 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=21no trial arm names this drug
Rebound acid hypersecretion10012.6
10.3–15.4ROR 12.6 · calibrated p 0.015 ✓
12.1 EB05 10.2 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=100no trial arm names this drug
Hyperparathyroidism secondary8112.3
9.9–15.4ROR 12.4 · calibrated p 0.016 ✓
11.8 EB05 9.7 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=81no trial arm names this drug
Nephrogenic anaemia14812.2
10.4–14.4ROR 12.2 · calibrated p 0.016 ✓
11.8 EB05 10.2 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=148no trial arm names this drug
Social anxiety disorder2011.7
7.5–18.3ROR 11.7 · calibrated p 0.024 ✓
10.4 EB05 6.7 · IC025 +2.4
3/3 methods agree
Not in label — unassessedserious n=20no trial arm names this drug
Antisocial behaviour3011.5
8.0–16.5ROR 11.5 · calibrated p 0.024 ✓
10.5 EB05 7.5 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=30 · ♀ 27% (drug 49%) · 100% consumerno trial arm names this drug
Gallbladder non-functioning1711.4
7.0–18.4ROR 11.4 · calibrated p 0.028 ✓
9.9 EB05 6.1 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious n=17no trial arm names this drug
Attention deficit hyperactivity disorder12111.2
–ROR 11.2 · –
–Not in label — unassessedserious n=121 · 92% consumerno trial arm names this drug
Self esteem decreased7011.0
8.7–14.0ROR 11.0 · calibrated p 0.025 ✓
10.5 EB05 8.5 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=70 · 100% consumerno trial arm names this drug
Biliary dyskinesia4911.0
8.3–14.6ROR 11.0 · calibrated p 0.026 ✓
10.3 EB05 8.0 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=49 · ♀ 100% (drug 49%)no trial arm names this drug
Foetal exposure during pregnancy2,31210.9
10.5–11.4ROR 11.4 · calibrated p 0.020 ✓
10.6 EB05 10.3 · IC025 +3.3
3/3 methods agree
Reporting / coding artifactserious PRR 7.3 · 100% consumerno trial arm names this drug
Drug abuse2,25210.3
9.9–10.8ROR 10.7 · calibrated p 0.025 ✓
10.1 EB05 9.7 · IC025 +3.3
3/3 methods agree
Reporting / coding artifactserious PRR 6.8 · 78% consumerno trial arm names this drug
Cholecystitis chronic18210.3
8.9–11.9ROR 10.3 · calibrated p 0.030 ✓
9.9 EB05 8.8 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious PRR 6.7 · ♀ 100% (drug 49%)no trial arm names this drug
Hepatitis c3069.6
8.6–10.7ROR 9.6 · calibrated p 0.037 ✓
9.3 EB05 8.5 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious PRR 6.6 · 96% consumerno trial arm names this drug

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Hydrocodone Bitartrate and Acetaminophen only as a background or rescue medication (NCT02625181, NCT04452344); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug dependence33,29596.4
95.6–97.2ROR 236.1 · calibrated p 9e-11 ✓
76.6 EB05 75.9 · IC025 +6.2
3/3 methods agree
Reporting / coding artifactserious PRR 52.1 · 98% consumerno trial arm names this drug
Overdose14,51126.8
26.4–27.2ROR 35.9 · calibrated p 1e-4 ✓
25.1 EB05 24.7 · IC025 +4.6
3/3 methods agree
Reporting / coding artifactserious PRR 21.1 · 97% consumerno trial arm names this drug
Pain12,0507.5
7.3–7.6ROR 9.2 · calibrated p 0.042 ✓
7.3 EB05 7.2 · IC025 +2.8
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious PRR 7.0 · 80% consumerno trial arm names this drug
Emotional distress10,84236.6
36.0–37.3ROR 45.2 · calibrated p 3e-5 ✓
33.4 EB05 32.9 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious PRR 23.6 · 94% consumerno trial arm names this drug
Drug withdrawal syndrome5,34524.0
23.3–24.6ROR 26.4 · calibrated p 5e-4 ✓
22.6 EB05 22.0 · IC025 +4.4
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 18.8 · 95% consumerno trial arm names this drug
Anxiety4,2035.6
5.4–5.7ROR 6.0 · calibrated p 0.153
5.5 EB05 5.4 · IC025 +2.4
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 4.6 · 85% consumerno trial arm names this drug
Death3,1811.4
1.3–1.4ROR 1.4 · calibrated p 0.580
1.4 EB05 1.3 · IC025 +0.4Outcome field, not a reaction
boxed warning mentions mortality
serious PRR 0.9 · 70% consumerno trial arm names this drug
Depression2,7284.5
4.3–4.7ROR 4.7 · calibrated p 0.271
4.5 EB05 4.3 · IC025 +2.1
3/3 methods agree
Labeled — boxed warning
exact term
serious PRR 4.0 · 89% consumerno trial arm names this drug
Learning disability2,407303.9
288.1–320.5ROR 317.5 · calibrated p 6e-12 ✓
166.7 EB05 161.2 · IC025 +7.3
3/3 methods agree
Not in label — unassessedserious n=2,403 · 99% consumerno trial arm names this drug
Foetal exposure during pregnancy2,31210.9
10.5–11.4ROR 11.4 · calibrated p 0.020 ✓
10.6 EB05 10.3 · IC025 +3.3
3/3 methods agree
Reporting / coding artifactserious PRR 7.3 · 100% consumerno trial arm names this drug
Drug abuse2,25210.3
9.9–10.8ROR 10.7 · calibrated p 0.025 ✓
10.1 EB05 9.7 · IC025 +3.3
3/3 methods agree
Reporting / coding artifactserious PRR 6.8 · 78% consumerno trial arm names this drug
Developmental delay2,240122.4
116.8–128.3ROR 127.5 · calibrated p 2e-8 ✓
92.1 EB05 88.9 · IC025 +6.4
3/3 methods agree
Not in label — unassessedserious PRR 62.2 · 99% consumerno trial arm names this drug
Disability1,76736.7
34.9–38.5ROR 37.8 · calibrated p 7e-5 ✓
33.4 EB05 32.1 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious PRR 23.0 · 95% consumerno trial arm names this drug
Completed suicide (death by suicide)1,7507.9
7.6–8.3ROR 8.2 · calibrated p 0.063
7.8 EB05 7.5 · IC025 +2.9
3/3 methods agree
Outcome field, not a reaction
boxed warning mentions mortality
serious PRR 5.2 · 91% clinicianno trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Hydrocodone Bitartrate And Acetaminophen ↔ Drug Dependence.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Hydrocodone Bitartrate and Acetaminophen?

In FDA FAERS, the most frequently co-reported reaction terms for Hydrocodone Bitartrate and Acetaminophen are pain, emotional distress, drug withdrawal syndrome, anxiety, depression, learning disability. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Hydrocodone Bitartrate and Acetaminophen have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of hydrocodone bitartrate extended-release tablets exposes patients and othe.

Do FAERS signals prove that Hydrocodone Bitartrate and Acetaminophen causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.